| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PLoSO...986692L |
| P356 | DOI | 10.1371/JOURNAL.PONE.0086692 |
| P932 | PMC publication ID | 3903567 |
| P698 | PubMed publication ID | 24475168 |
| P5875 | ResearchGate publication ID | 259961399 |
| P2093 | author name string | Qiang Liu | |
| Zhiyong Wu | |||
| Xuebao Zheng | |||
| Ruxi Lv | |||
| Shixue Dai | |||
| Weiguang Qiao | |||
| Yinjun Wang | |||
| P2860 | cites work | Cochrane Database of Systematic Reviews | Q15750361 |
| Guidelines for the management of inflammatory bowel disease in adults | Q22242049 | ||
| Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis | Q24245033 | ||
| Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus | Q26852581 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 | ||
| Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease | Q34394083 | ||
| Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. | Q35595821 | ||
| Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis | Q35919991 | ||
| Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease | Q37183149 | ||
| Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis | Q37853359 | ||
| A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis | Q37892444 | ||
| Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis | Q38056807 | ||
| Infliximab in the treatment of steroid-dependent ulcerative colitis | Q42644450 | ||
| Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab | Q44742543 | ||
| Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study | Q45110916 | ||
| One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. | Q45913034 | ||
| Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis | Q46184125 | ||
| Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis | Q46286038 | ||
| Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. | Q46531976 | ||
| Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. | Q46875109 | ||
| Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis | Q46990369 | ||
| Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. | Q50552144 | ||
| Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. | Q50856499 | ||
| Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. | Q50891880 | ||
| The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. | Q51906579 | ||
| Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. | Q53122367 | ||
| Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. | Q54007642 | ||
| Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial | Q59120396 | ||
| Tumour necrosis factor alpha in stool as a marker of intestinal inflammation | Q67512879 | ||
| Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine | Q68350435 | ||
| Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease | Q72462916 | ||
| Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids | Q80543381 | ||
| Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients | Q80606867 | ||
| Ulcerative colitis | Q84851901 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e86692 | |
| P577 | publication date | 2014-01-27 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis | |
| P478 | volume | 9 |
| Q26775384 | A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases |
| Q34353032 | A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases |
| Q28541247 | A systems biology-based approach to uncovering the molecular mechanisms underlying the effects of dragon's blood tablet in colitis, involving the integration of chemical analysis, ADME prediction, and network pharmacology |
| Q86373852 | Chemoprevention of colorectal cancer |
| Q41238509 | Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs |
| Q28070298 | Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials |
| Q28084236 | Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis |
| Q91994732 | Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses |
| Q34728538 | Endometrial regenerative cells as a novel cell therapy attenuate experimental colitis in mice |
| Q47607083 | Foeniculum vulgare essential oil ameliorates acetic acid-induced colitis in rats through the inhibition of NF-kB pathway |
| Q47147682 | Regulatory role of NKG2D+ NK cells in intestinal lamina propria by secreting double-edged Th1 cytokines in ulcerative colitis |
| Q37662503 | Second Korean guidelines for the management of ulcerative colitis. |
Search more.